Autolus Therapeutics (AUTL) Net Income towards Common Stockholders (2017 - 2026)

Autolus Therapeutics (AUTL) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$90.4 million in Q4 2025.

• Quarterly Net Income towards Common Stockholders fell 227.32% year-over-year to -$90.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$287.6 million (down 30.32% YoY) and the FY2025 annual result came in at -$287.6 million, down 30.32% from the prior year.
• Net Income towards Common Stockholders slipped to -$90.4 million in Q4 2025, from -$79.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$27.0 million in Q4 2022 to a low of -$90.4 million in Q4 2025.
• A 5-year average of -$50.4 million and a median of -$44.2 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 64.23% — and 2025, when it tumbled 227.32%.
• Tracing AUTL's Net Income towards Common Stockholders over 5 years: stood at -$41.7 million in 2021, then soared by 35.31% to -$27.0 million in 2022, then tumbled by 186.04% to -$77.2 million in 2023, then jumped by 64.23% to -$27.6 million in 2024, then plunged by 227.32% to -$90.4 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$90.4 million (Q4 2025), -$79.1 million (Q3 2025), and -$47.9 million (Q2 2025), per Business Quant data.